China Biologic's ex-CEO throws his hat in the ring

Former chief of the Nasdaq-listed biotechnlogy firm launches a $3.9 billion bid to take it private. His consortium of backers face a potential battle to bring back ownership to China.

A consortium led by former boss David Gao has filed an all-cash $3.9 billion offer for Nasdaq-listed China Biologic Products, topping an existing bid by Citic Capital Holdings  as the battle to take the plasma treatment provider private heats up anew. 

Former chief executive and chairman Gao, who led the company for six years before stepping down after Citic's  $3.6 billion  offer in June, is backed by GL Capital Group, Bank of China Group Investment Limited and CDH Investments.

In a press release on Monday, China Biologic said the new proposal provided immediate and significant value...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222